

Committee for the Japanese Clinical Practice Guidelines for the Management of Sepsis and Septic Shock 2024

- Member's names, conflicts of interest (COI), and roles -

Panelists, Organizers

Name	Position	Area of GL	Academic COI		Financial COI													
			Position in academic society	Contribution to other GL	A-1	A-2	A-3	A-4	A-5	A-6	A-7	A-8	A-9	B-1	B-2	B-3	C-1	C-2
Nobuaki Shime	Chairparson		Japanese Society of Intensive Care Medicine (director) Japanese Society of Respiratory Care Medicine (director) Japanese Society of Pediatric Intensive and Critical Care (director)	JRS Guidelines for the Management of Pneumonia in Adults	No	No	No	Gilead (2021) /BD (2022) /Asahi-Kasei Pharma (2023)	No	No	Asahi-Kasei Pharma (2021/2022/2023)	No	No	No	No	No	No	No
Taka-aki Nakada	Chairparson				Smart119 (2021/2022/2023)	Smart119 (2021/2022/2023)	No	No	No	No	Nihon Kohden (2021)	No	No	No	No	No	No	No
Yoshitaka Aoki	Panelist	AC			No	No	No	No	No	No	No	No	No	No	No	No	No	No
Shigeaki Inoue	Panelist	WG7, WG8, PR			No	No	No	No	No	No	No	No	No	No	No	No	No	No
Toshiaki Iba	Panelist	WG6			No	No	No	Japan Blood Products Organization (2022/2023) / Toray Medical (2022)	No	JIMRO (2023)	Asahi-Kasei Pharma (2021/2022/2023)	No	No	No	No	No	No	No
Moritoki Egi	Panelist, Director	WG2, WG6	Japanese Society of Intensive Care Medicine (director)	ARDS clinical practice guideline 2021	No	No	No	No	No	No	No	No	No	No	No	No	No	No
Hiroshi Ogura	Panelist	WG1, Scenario			No	No	No	No	No	No	No	No	No	No	No	No	No	No
Yusuke Kawai	Panelist	WG8	Japanese Society for Early Mobilization (director)	Japanese Clinical Practice Guidelines for Rehabilitation in Critically Ill Patients 2023 Clinical practice guidelines on tracheal suctioning 2023; for adults with artificial airway	No	No	No	No	No	No	No	No	No	No	No	No	No	No
Atsushi Kawaguchi	Panelist	WG9		Japanese Practice Guidelines for Inter-hospital Transport of Critically ill Patients	Konica Minolta (2023)	No	No	No	No	Fisher & Paykel Healthcare (2023)	No	No	No	No	No	No	No	No

Tatsuya Kawasaki	Panelist	WG9		ARDS clinical practice guideline2021 Japanese rapid/living recommendations on drug management for COVID-19 Consensus statement on Children with multisystem inflammatory syndrome associated with COVID-19(MIS-C/PIMS) Japanese Clinical Practice Guidelines for Rehabilitation in Critically Ill Patients2023 Operational Guideline on Rapid Response System	No	No	No	No	No	No	No	No	No	No	No	No	No
Shigeki Kushimoto	Panelsit, Director		Japanese Association for Acute Medicine (director) Japanese Society of Intensive Care Medicine (director) Japanese Society for the Acute Care Surgery (director) Japanese Society for Abdominal Emergency Midicine (director) Japanese College of Surgeons (director) Japan Trauma Care and Research (director) Japanese Association for the Surgery of Trauma (director) General social foundation Japan Skin Bank Network (supervisor)	Transfusion Guideline for patients with Massive Bleeding Revised Guidelines for the Establishment and Operation of Remote ICUs Japanese Practice Guidelines for Inter-hospital Transport of Critically ill Patients Japan Advanced Trauma Evaluation and Care Guidelines DIC clinical practice guideline Japan Expert Trauma Evaluation and Care Guidelines	No	No	No	No	No	No	No	No	No	No	No	No	No
Yutaka Kondo	Panelist	WG2		Japanese Clinical Practice Guidelines for Rehabilitation in Critically Ill Patients2023 Heatstroke Guideline 2024 JCS 2022 Guideline on Perioperative Cardiovascular Assessment and Management for Non-cardiac Surgery ARDS clinical practice guideline2021	No	No	No	No	No	No	No	Topp an (2021~)	No	No	No	No	No
Masaaki Sakuraya	Panelist	WG3		ARDS clinical practice guideline2021	No	No	No	No	No	No	No	No	No	No	No	No	No
Shunsuke Taito	Panelist	WG7		ARDS clinical practice guideline2021 Japanese Clinical Practice Guidelines for Rehabilitation in Critically Ill Patients 2023	No	No	No	No	No	No	No	No	No	No	No	No	No
Kent Doi	Panelist	WG4, Databank, Scenario	Japan Society for Blood Purification in Critical Care (chairperson)	Guidelines for treatment of renal injury during cancer chemotherapy 2022	No	No	No	Asahi-Kasei Pharma (2023)	No	Nipro (2022)	No	No	No	No	No	No	No

Hideki Hashimoto	Panelist	WG1		Japanese Practice Guidelines for Inter-hospital Transport of Critically ill Patients Japanese rapid/living recommendations on drug management for COVID-19	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No
Yoshitaka Hara	Panelist	WG4			No	No	No	No	No	No	No	No	No	No	No	No	No	No	No
Tatsuma Fukuda	Panelist	WG3		JRC Guideline 2025	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No
Asako Matsushima	Panelist	WG3	Japanese Association for Acute Medicine (director)	Clinical Practice Guidelines for Management of Burn Care Surviving Sepsis After Burn Campaign	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No
Tomoaki Yatabe	Vice chairparson	WG6		ARDS clinical practice guideline2021	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No
Kazuma Yamakawa	Vice chairparson	WG5		DIC clinical practice guideline	No	No	No	Japan Blood Products Organization (2022/2023)	No	Japan Blood Products Organization (2023) /JIMRO (2021) /Fujimori Kogyo (2023)	Asahi-Kasei Pharma (2021/2022/2023)	No	No	No	No	No	No	No	No

Academic Guideline Promotion Team members

[illegible]

Hiromu Okano	AC			ARDS clinical practice guideline2021 Clinical practice guidelines on tracheal suctioning 2023; for adults with artificial airway Japanese rapid/living recommendations on drug management for COVID-19 Neurointensive Care Guideline Japanese Practice Guidelines for Inter-hospital Transport of Critically ill Patients	No	No	No	No	No	No	No	No	No	No	No	No	No
Ryuta Onodera	AC			Heatstroke Guideline	No	No	No	No	No	No	No	No	No	No	No	No	No
Ken-ichi Kano	AC,WG	WG2,PR		ARDS clinical practice guideline2021 Heatstroke Guideline 2024 Practice Guidelines for Primary Care of Acute Abdomen 2024 Japanese Guidelines for Nutrition Support Therapy in the Critically Ill Patients	No	No	No	No	No	No	No	No	No	No	No	No	No
Sadatoshi Kawakami	AC,WG	WG3			No	No	No	No	No	No	No	No	No	No	No	No	No
Akira Kawakami	AC,WG,SR	WG2			No	No	No	No	No	No	No	No	No	No	No	No	No
Yusuke Kawamura	AC,WG,SR	WG7,PR			No	No	No	No	No	No	No	No	No	No	No	No	No
Kazuya Kikutani	AC			Japanese Practice Guidelines for Inter-hospital Transport of Critically ill Patients	No	No	No	No	No	No	No	No	No	No	No	No	No
Yuki Kotani	AC,WG	WG3			No	No	No	No	No	No	No	No	No	No	No	No	No
Masaki Takahashi	AC	WG9			No	No	No	No	No	No	No	No	No	No	No	No	No
Chikashi Takeda	AC				No	No	No	No	No	No	No	No	No	No	No	No	No
Takero Terayama	AC			Neurointensive Care Guideline Japanese Practice Guidelines for Inter-hospital Transport of Critically ill Patients ARDS clinical practice guideline2021 Japanese rapid/living recommendations on drug management for COVID-19	No	No	No	Gilead (2022)	Yodoshu Publishing (2021)	JA-Kyosai (2022)	No	No	No	No	No	No	No
Satoshi Nakajima	AC			Heatstroke Guideline 2024	No	No	No	No	No	No	No	No	No	No	No	No	No
Katsuhiko Hashimoto	AC,WG	WG6			No	No	No	No	No	No	No	Yes	No	No	No	No	No

Junta Honda	AC	WG6			No	No	No	No	No	No	No	No	No	No	No	No	No	No
Yuto Makino	AC,WG,SR	WG5			No	No	No	No	No	No	No	No	No	No	No	No	No	No
Tsuguhiro Matsumoto	AC				No	No	No	No	No	No	No	No	No	No	No	No	No	No
Akito Mizuno	AC	WG4			No	No	No	No	No	No	No	No	No	No	No	No	No	No
Sohma Miyamoto	AC	WG3			No	No	No	No	No	No	No	No	No	No	No	No	No	No
Shunsuke Yasuo	AC,SR	WG5		ARDS clinical practice guideline 2021 Heatstroke Guideline 2024	No	No	No	No	No	No	No	No	No	No	No	No	No	No
Yuki Wakabayashi	AC,WG,SR	WG3		Japanese Clinical Practice Guidelines for Rehabilitation in Critically Ill Patients 2023	No	No	No	No	No	No	No	No	No	No	No	No	No	No
Takeshi Wada	AC	WG5, Scenario			No	No	No	Asahi - Kasei Pharma (2022/2023) Japan Blood Products Organization (2022)	No	Takeda Science Foundation (2021)	No	No	No	No	No	No	No	No

Working group members

[illegible]

[illegible]

[illegible]

Systematic review members

Namo

Position

Area of GI

Academic COI

Financial COI

[illegible]

Guideline related working group member

1

0

Ryo Ishizawa	WG	Aap			No	No	No	No	No	No	No	No	No	No	No	No	No	No
Yusuke Itosu	WG	PR			No	No	No	No	No	No	No	No	No	No	No	No	No	No
Hiroyasu Inoue	WG	Aap		Clinical practice guidelines on physical therapy: revision 2021 Japanese Clinical Practice Guidelines for Rehabilitation in Critically Ill Patients 2023	No	No	No	No	No	No	No	No	No	No	No	No	No	No
Masatoshi Uchida	WG	Databank			No	No	No	No	No	No	No	No	No	No	No	No	No	No
Yohei Okada	WG	LLM for SR		ARDS clinical practice guideline	No	No	No	No	No	No	No	No	No	No	No	No	No	No
Yoshihito Ogawa	WG	Scenario			No	No	No	No	No	No	No	No	No	No	No	No	No	No
Daisuke Kawakami	WG	PR		ARDS clinical practice guideline 2021	No	No	No	No	No	No	No	No	No	No	No	No	No	No
Tadanaga Shimada	WG	Databank			No	No	No	No	No	No	No	No	No	No	No	No	No	No
Junko Tatsuno	WG	Aap	Japanese Association for Emergency Nursing (director)	Japanese Clinical Practice Guidelines for Rehabilitation in Critically Ill Patients 2023 Japanese Guidelines for Nutrition Support Therapy in the Critically Ill Patients	No	No	No	No	No	No	No	No	No	No	No	No	No	No
Yuki Togami	WG	Aap			No	No	No	No	No	No	No	No	No	No	No	No	No	No
Yoshinori Tomoda	WG	Aap			No	No	No	No	No	No	No	No	No	No	No	No	No	No
Tomoya Hirose	WG	Aap			No	No	No	No	No	No	No	No	No	No	No	No	No	No
Ryo Fujii	WG	Scenario		ARDS clinical practice guideline 2021	No	No	No	No	No	No	No	No	No	No	No	No	No	No
Koichiro Homma	WG	Scenario			No	No	No	No	No	No	No	No	No	No	No	No	No	No
Hiromasa Yakushiji	WG	Aap			No	No	No	CSL Behring (2021/2022/2023) Takeda Pharmaceutical (2021/2022/2023) Vexon International (2021/2022/2023)	No	No	No	No	No	No	No	No	No	No

【Policy of COI disclosure】

・ The Japanese Society of Intensive Care Medicine and the Japanese Association for Acute Medicine submitted this COI disclosure jointly, based on the same policy issued by the Japanese Association of Medical Sciences.

- Both groups used the modified submission format provided by the Japanese Association of Medical Sciences.
- In accordance with these guidelines, organizations are only required to disclose COI that relate to associated companies or for-profit organizations as financial COI.
- We asked all members to submit their financial and academic COI for the past three years, in accordance with the current policy, shown in the last table.

Standard of conflict of interest disclosure		
Financial COI	A-1	Presence of officer or advisor of for-profit company or organization, or received any remuneration (list those where the remuneration amount from one company/ organization is 1 million yen or more per year)
	A-2	Holding of shares or profits obtained from those shares (profit from shares in the last year) (list those where the annual profit of one company is 1 million yen or more, or those who own more than 5% of shares)
	A-3	Remuneration paid as a patent royalty from for-profit company or organization (list those where one patent royalty was 1 million yen or more)
	A-4	Remuneration such as a daily allowance, lecture fee, etc. paid for the time and labor requested by the researcher by a for-profit company or organization for attending meeting (e.g., presentation, advising) (list the lecture fee from one company/organization based on the annual total amount)
	A-5	Manuscript fee paid for writing a pamphlet, roundtable article, etc. created by a for-profit company or organization
	A-6	Research funds provided by a for-profit company or organization (list those where 1 million yen or more were actually allocated with a research contract from a one company/organization for medical research [e.g., joint research, contract research, clinical trial] that allows the filer to substantially decide the purpose of use)
	A-7	Scholarship (incentive) donations provided by a for-profit company or organization (list donations over 1 million yen actually allocated to the individual filer or the course/field of laboratory with which the filer is affiliated, where they can substantially decide the purpose of use)
	A-8	Donation courses provided by companies, etc.(list donations of over 1 million yen actually allocated and can be used for practical purposes)
	A-9	Other remuneration (travel, gifts, etc. that are not directly related to research)(list based on the annual remuneration received from one company/organization)
	B-1	Presence of officer or advisor of for-profit company or organization, or received any remuneration (list based on the annual remuneration from one company/ organization)
	B-2	Holding of shares or profits obtained from those shares (profit from shares in the last year) (list the total annual profits of one company, or those holding 5% or more of shares)
	B-3	Remuneration paid as a patent royalty from for-profit company or organization (list those where one patent royalty was 1 million yen or more)
	C-1	Research funds provided by a for-profit company or organization (list those where research contract money was actually allocated for medical research [e.g., joint research, contract research] based on one company/organization or contract, where the applicable head of the organization/department could substantially determine the purpose of use)
	C-2	Scholarship (incentive) donations provided by a for-profit company or organization (list those where the donation was actually allocated from one company/for-profit organization with filer's research, and where the head of the research institution, hospital, faculty, center, or course could substantially determine the purpose of use)
Academic COI		Position higher than academic society director or auditor
		Involvement in the development of other guidelines